All CoverageFirst-Line HIV TreatmentImmediate HIV Treatment Initiation With Integrase Inhibitors Leads to Large Drop in Secondary HIV Transmission Among MSMTerri Wilder, M.S.W.; Myles HelfandQ&A11 Min ReadIntegrase inhibitors are known to be potent first-line therapy options. Recent research suggests their benefits extend to onward HIV prevention as well. First-Line HIV TreatmentImmediate HIV Treatment Initiation With Integrase Inhibitors Leads to Large Drop in Secondary HIV Transmission Among MSMTerri Wilder, M.S.W.; Myles HelfandQ&A11 Min ReadIntegrase inhibitors are known to be potent first-line therapy options. Recent research suggests their benefits extend to onward HIV prevention as well. Education & Risk ManagementThis Week in HIV Research: What We Don’t Know Hurts ThemBarbara Jungwirth; Myles HelfandNews1 Min ReadAug. 20, 2020: HIV knowledge and stigma among health care workers in the southern U.S.; condomless sex vs. HIV risk among MSM; how drug class choice may affect onward transmission risk; STI screening rates among MSM on PrEP. Education & Risk ManagementThis Week in HIV Research: What We Don’t Know Hurts ThemBarbara Jungwirth; Myles HelfandNews1 Min ReadAug. 20, 2020: HIV knowledge and stigma among health care workers in the southern U.S.; condomless sex vs. HIV risk among MSM; how drug class choice may affect onward transmission risk; STI screening rates among MSM on PrEP. Antiretroviral TherapyThis Week in HIV Research: Playing Catchup on the Aging FrontBarbara Jungwirth; Myles HelfandSlideshowMarch 12, 2020: The impact of age on viral suppression and immunologic recovery; chronic obstructive pulmonary disease risk among older PLWHIV; sex-based differences in older men vs. women; effect of aging on drug-drug interactions. Antiretroviral TherapyThis Week in HIV Research: Playing Catchup on the Aging FrontBarbara Jungwirth; Myles HelfandSlideshowMarch 12, 2020: The impact of age on viral suppression and immunologic recovery; chronic obstructive pulmonary disease risk among older PLWHIV; sex-based differences in older men vs. women; effect of aging on drug-drug interactions. Adverse Events & ComorbiditiesThis Week in HIV Research: Bone Concerns Aren’t Just for Older FolksBarbara Jungwirth; Myles HelfandNews1 Min ReadJan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function. Adverse Events & ComorbiditiesThis Week in HIV Research: Bone Concerns Aren’t Just for Older FolksBarbara Jungwirth; Myles HelfandNews1 Min ReadJan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function. Darunavir (Prezista)Boosted Darunavir Is Associated With Higher Cardiovascular Risk in D:A:D Study, but Not AtazanavirSimon Collins; HIV i-Base4 Min ReadCumulative use of the boosted protease inhibitor darunavir/ritonavir was associated with an approximately 60% higher rate of developing heart disease over five years, in an analysis from the D:A:D study. Darunavir (Prezista)Boosted Darunavir Is Associated With Higher Cardiovascular Risk in D:A:D Study, but Not AtazanavirSimon Collins; HIV i-Base4 Min ReadCumulative use of the boosted protease inhibitor darunavir/ritonavir was associated with an approximately 60% higher rate of developing heart disease over five years, in an analysis from the D:A:D study. Darunavir (Prezista)No Increased Risk of Birth Defects With Darunavir: Findings From the Antiretroviral Pregnancy RegistryPolly Clayden; HIV i-Base3 Min ReadThe Antiretroviral Pregnancy Registry found no apparent increase in the frequency of specific birth defects with first trimester darunavir exposure. Darunavir (Prezista)No Increased Risk of Birth Defects With Darunavir: Findings From the Antiretroviral Pregnancy RegistryPolly Clayden; HIV i-Base3 Min ReadThe Antiretroviral Pregnancy Registry found no apparent increase in the frequency of specific birth defects with first trimester darunavir exposure. Darunavir (Prezista)Updates for Prezista (Darunavir) for Use in Pregnant WomenU.S. Food and Drug AdministrationNews5 Min ReadOn June 17, 2016, the U.S. Food and Drug Administration approved updates to the Prezista (darunavir) labeling to include information on the use of darunavir in pregnant women. Darunavir (Prezista)Updates for Prezista (Darunavir) for Use in Pregnant WomenU.S. Food and Drug AdministrationNews5 Min ReadOn June 17, 2016, the U.S. Food and Drug Administration approved updates to the Prezista (darunavir) labeling to include information on the use of darunavir in pregnant women. Perinatal Care & PregnancyPharmacokinetics in Pregnancy: Darunavir/Ritonavir and EtravirinePolly Clayden; HIV i-BaseNews3 Min ReadTwo small studies presented at the 5th International Workshop on HIV & Women evaluated the pharmacokinetics of darunavir/ritonavir (DRV/r) and etravirine (ETV) respectively in pregnancy. In both studies drug exposure was altered -- lower for DRV and ... Perinatal Care & PregnancyPharmacokinetics in Pregnancy: Darunavir/Ritonavir and EtravirinePolly Clayden; HIV i-BaseNews3 Min ReadTwo small studies presented at the 5th International Workshop on HIV & Women evaluated the pharmacokinetics of darunavir/ritonavir (DRV/r) and etravirine (ETV) respectively in pregnancy. In both studies drug exposure was altered -- lower for DRV and ... Darunavir (Prezista)Equivalent Efficacy With Lower Dose DarunavirPolly Clayden; HIV i-Base6 Min ReadA reduced dose of darunavir boosted with ritonavir was effective in two reports from Italy and Spain. Darunavir (Prezista)Equivalent Efficacy With Lower Dose DarunavirPolly Clayden; HIV i-Base6 Min ReadA reduced dose of darunavir boosted with ritonavir was effective in two reports from Italy and Spain. Raltegravir (Isentress)Dual Therapy With Raltegravir and DarunavirSean R. Hosein; Canadian AIDS Treatment Information Exchange7 Min ReadThe leading U.S. HIV treatment guidelines developed by the U.S. Department of Health and Human Services (DHHS) for adults have several regimens that it recommends from which doctors and their patients can choose for the initial therapy of HIV. These ... Raltegravir (Isentress)Dual Therapy With Raltegravir and DarunavirSean R. Hosein; Canadian AIDS Treatment Information Exchange7 Min ReadThe leading U.S. HIV treatment guidelines developed by the U.S. Department of Health and Human Services (DHHS) for adults have several regimens that it recommends from which doctors and their patients can choose for the initial therapy of HIV. These ... Atazanavir (Reyataz)Atazanavir, Raltegravir and Darunavir Virologically Equivalent in Naive Patients but Significant Differences for Tolerability: Results From ACTG 5257Simon Collins; HIV i-BaseNews4 Min ReadPrimary results from the ACTG 5257 study shifted the assumed relative parity between three of the preferred first-line combinations in US DHHS guidelines. Raphael Landovitz from University of California Los Angeles, presented results at CROI 2014 fro... Atazanavir (Reyataz)Atazanavir, Raltegravir and Darunavir Virologically Equivalent in Naive Patients but Significant Differences for Tolerability: Results From ACTG 5257Simon Collins; HIV i-BaseNews4 Min ReadPrimary results from the ACTG 5257 study shifted the assumed relative parity between three of the preferred first-line combinations in US DHHS guidelines. Raphael Landovitz from University of California Los Angeles, presented results at CROI 2014 fro... Adverse Events & ComorbiditiesDarunavir-Ritonavir Monotherapy: Impact on Fat and BonesSean R. Hosein; Canadian AIDS Treatment Information Exchange2 Min ReadDarunavir is a powerful protease inhibitor. In a previous trial called Monet, results showed that switching to darunavir-ritonavir monotherapy from standard triple therapy (ART) is roughly as effective as ART. The Monarch Study In a substudy of a t... Adverse Events & ComorbiditiesDarunavir-Ritonavir Monotherapy: Impact on Fat and BonesSean R. Hosein; Canadian AIDS Treatment Information Exchange2 Min ReadDarunavir is a powerful protease inhibitor. In a previous trial called Monet, results showed that switching to darunavir-ritonavir monotherapy from standard triple therapy (ART) is roughly as effective as ART. The Monarch Study In a substudy of a t...
